Though glycopyrrolate is generally well-tolerated, it can cause a range of anticholinergic side effects, particularly when administered in higher doses. Common adverse effects include dry mouth, constipation, blurred vision, tachycardia, and urinary retention. These effects are related to the inhibition of muscarinic receptors in various tissues, which leads to reduced secretions, decreased GI motility, and impaired smooth muscle contraction in the bladder.
One of the significant advantages of glycopyrrolate over other anticholinergics like atropine or scopolamine is its inability to cross the blood-brain barrier, reducing the risk of CNS-related adverse effects such as confusion, agitation, or delirium. However, patients with angle-closure glaucoma, prostatic hypertrophy, or bladder neck obstruction should avoid glycopyrrolate due to the risk of exacerbating these conditions.
In rare cases, glycopyrrolate can cause hyperthermia and heat prostration due to its inhibition of sweating. This is particularly important in patients exposed to high ambient temperatures or those engaging in physical exercise. In addition, glycopyrrolate should be used cautiously in patients with renal impairment, as its excretion is primarily through the urinary system.
Pharmacokinetics and Administration
Glycopyrrolate has a rapid onset of action, typically within 1 minute when administered intravenously (15 to 30 minutes intramuscularly), and an elimination half-life of about 50 minutes. Its vagal-blocking effect on heart rate lasts 2 to 3 hours and its drying effect on secretions up to 7 hours, so its duration of action is usually quoted as 2 to 4 hours, which is longer than atropine's 30 to 60 minutes of heart rate effect, making it ideal for use in both short and longer surgical procedures. Glycopyrrolate can be administered via intravenous, intramuscular, oral, or topical routes, depending on the clinical scenario.
For preoperative use, glycopyrrolate is typically administered intravenously or intramuscularly at doses of 0.005 to 0.01 mg/kg in children (the label dose is 0.004 mg/kg, maximum 0.1 mg per dose), and 0.2 to 0.4 mg in adults; intraoperative bradycardia is treated with 0.1 to 0.2 mg intravenously, repeated every 2 to 3 minutes as needed. For reversal of neuromuscular blockade the dose is 0.2 mg per 1 mg of neostigmine. Oral formulations are available in tablet and solution forms for long-term management of conditions like COPD and chronic drooling in pediatric patients with neurologic disorders. A topical formulation is also available to treat primary axillary hyperhidrosis.
| Parameter | Glycopyrrolate |
|---|---|
| Onset, intravenous | Typically within 1 minute |
| Elimination half-life | About 50 minutes |
| Duration of action | About 2 to 4 hours — longer than atropine |
| Routes available | Intravenous, intramuscular, oral, or topical |
| Preoperative dose, children | 0.005 to 0.01 mg/kg IV or IM (label 0.004 mg/kg, maximum 0.1 mg per dose) |
| Preoperative dose, adults | 0.2 to 0.4 mg IV or IM |
| Intraoperative bradycardia | 0.1 to 0.2 mg IV, repeat every 2 to 3 minutes as needed |
| Reversal with neostigmine | 0.2 mg glycopyrrolate per 1 mg neostigmine |
| Elimination caution | Excreted primarily in the urine; use cautiously in renal impairment |
